A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study

By Rose P.G.   Rodriguez M.   Walker J.   Greer B.   Fusco N.   McGuire W.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 136-139

Elsevier

Access to resources Recommend Favorite

Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience

By                    

Oncology Letters, Vol. 5, Iss. 1, 2013-01 ,pp. : 35-38

Spandidos Publications

Access to resources Recommend Favorite

Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study

By Thigpen J.T.   Blessing J.A.   Olt G.   Lentz S.S.   Bell J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 581-586

Elsevier

Access to resources Recommend Favorite

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

By Safra Tamar   Ron Ilan   Boaz Mona   Brenner Joseph   Grisaru Dan   Inbar Moshe   Hayat Henry   Menczer Joseph   Golan Abraham   Levy Tally  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 463-468

Informa Healthcare

Access to resources Recommend Favorite

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel - The Memorial Sloan-Kettering Cancer Center experience

By Dizon D.S.   Dupont J.   Anderson S.   Sabbatini P.   Hummer A.   Aghajanian C.   Spriggs D.  

Gynecologic Oncology, Vol. 91, Iss. 3, 2003-12 ,pp. : 584-590

Elsevier

Access to resources Recommend Favorite